| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1377433 | Bioorganic & Medicinal Chemistry Letters | 2007 | 8 Pages |
Abstract
The design, synthesis, and SAR of a novel series of heterobiaryl phenethanolamine β3 adrenergic receptor agonists are described. The furan analogue 49 was shown to elicit a significant dose-dependent lowering of plasma glucose in a rodent model of type 2 diabetes.
Graphical abstractThe design, synthesis, and SAR of a novel series of heterobiaryl phenethanolamine β3 adrenergic receptor agonists are described. The furan analogue 49 was shown to elicit a significant dose-dependent lowering of plasma glucose in a rodent model of type 2 diabetes.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Barry G. Shearer, Esther Y. Chao, David E. Uehling, David N. Deaton, Conrad Cowan, Bryan W. Sherman, Tula Milliken, Walter Faison, Kathleen Brown, Kimberly K. Adkison, Frank Lee,